$4.29
-0.69%SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Flat FCF growth. Stable but not expandingโmonitor for signs of business maturity or temporary headwinds.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
SIGA โข NASDAQ
| SIGA Technologies, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
59.2M | 59.2M | 68.1M | 33.9M | 69.5M | 56.3M | -7.2M | 421.8M | -36.2M | -39.7M | -39.5M | -265.5M | -17.2M | -14.5M | 13.6M | -28.2M | -17.6M | -8.6M | -5.6M | -9.9M | |
538.4K | 538.4K | 538.3K | 517.6K | 522.4K | 529.8K | 527K | 69.6K | 132.2K | 174.3K | 247.4K | 351.6K | 463.1K | 419.4K | 568.3K | 625.3K | 475.1K | 459.9K | 1.2M | 1.6M | |
193.4K | 193.4K | -4.8M | -3.8M | 121.4K | 11.6M | -2.4M | -9.3M | -2.7M | 2.7M | 243.7K | -659.1K | 73.8K | 0.0 | -13.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.6M | 3.6M | 2.1M | 1.8M | 1.3M | 1.4M | 2.1M | 2.3M | 1.1M | 775.5K | 1.6M | 2.4M | 2.3M | 1.8M | 12.5M | 1.5M | 2.1M | 0.0 | 0.0 | 0.0 | |
-23.1M | -10.1M | 579.2K | -199.2K | 501K | 9.4M | -594K | -348.9M | 21.2M | 1.8M | 10.1K | -546.7K | 48.8K | -335.9K | 4.7M | 15.9M | 5.7M | 997.8K | -859.4K | 3.7M | |
(8.2M) | (30.4M) | (3.5M) | (31.4M) | (1.1M) | (3.7M) | (0.0) | (252K) | (325K) | (501K) | (0.0) | (728.4K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
8.3M | -4.7M | 28.4M | 9.4M | -60.4M | -7.7M | -10.6M | 2.9M | 8.3M | -81.3M | 48.5M | 278.1M | 72.8M | -7.6M | 7.9M | -686.4K | 789.8K | -56.2K | -198.8K | 187.8K | |
48.8M | 48.8M | 94.8M | 41.6M | 11.5M | 71.5M | -18.2M | 68.9M | -8.2M | -115.6M | 11.1M | 14.2M | 58.4M | -20.2M | 25.6M | -10.8M | -8.5M | -7.2M | -5.4M | -4.4M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-42.5K | -42.5K | -21.7K | (0.0) | -50.6K | -15.5K | -29.1K | -102.3K | -100.1K | -23.9K | -109K | -28K | -857.3K | -588.2K | -237K | -549.9K | -340.7K | -340.2K | -1.2M | -884.2K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (237K) | (549.9K) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -25M | -41.2M | -5M | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 40M | 31.3M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 78.3M | 0.0 | 1.2M | 4M | -3.4M | 0.0 | -1.3M | -237K | -549.9K | 0.0 | 0.0 | 0.0 | 0.0 | |
-42.5K | -42.5K | -21.7K | (0.0) | -50.6K | -15.5K | -29.1K | (78.2M) | -100.1K | (1.2M) | (3.9M) | -3.5M | -857.3K | -1.9M | (14.8M) | -10.5M | -5.3M | -340.2K | -1.2M | -884.2K | |
FINANCING ACTIVITIES | ||||||||||||||||||||
0.0 | 0.0 | -11.1M | -13M | -26M | -28.5M | 0.0 | 0.0 | -591.1K | 34.6M | 0.0 | -415.9K | -179K | 0.0 | -1.4M | 0.0 | 18.6M | 3.2M | 3M | 14.3M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -85.9M | 0.0 | 0.0 | 0.0 | 28.7M | -2M | -2M | -1M | 4.9M | 0.0 | 0.0 | 0.0 | 0.0 | -130.3K | -107.5K | |
-43.1M | -42.7M | -32.1M | -32.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | -11.1M | -13M | -26M | -28.5M | -1.2M | -4.1M | -591.1K | -428K | (0.0) | -415.9K | -179K | (0.0) | -1.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-348.4K | -799.9K | -214.8K | -12.5K | -173.9K | -184K | -1.2M | -3.8M | 5.5K | -32.9M | -3.3K | 102K | 2.9M | 9.6K | 3.9M | 13.2M | 7.4M | -159K | 0.0 | 0.0 | |
-43.5M | -43.5M | -43.4M | -46M | -26.2M | -114.6M | -1.2M | -3.8M | -585.6K | 30.4M | -2M | -2.3M | 1.7M | 4.9M | 2.6M | 13.2M | 26M | 3M | 2.9M | 14.2M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
5.3M | 5.3M | 51.4M | -4.3M | -14.8M | -43.1M | -19.4M | 143.3M | -8.8M | -84M | 13M | 8.4M | 59.3M | -17.2M | 42.9M | -8.2M | 12.2M | -4.5M | -3.8M | 8.9M | |
150.1M | 150.1M | 98.8M | 103.1M | 117.9M | 161M | 180.4M | 37.1M | 28.7M | 112.7M | 99.7M | 91.3M | 32M | 49.3M | 6.3M | 14.5M | 2.3M | 6.8M | 10.6M | 1.8M | |
155.4M | 155.4M | 150.1M | 98.8M | 103.1M | 117.9M | 161M | 180.4M | 19.9M | 28.7M | 112.7M | 99.7M | 91.3M | 32M | 49.3M | 6.3M | 14.5M | 2.3M | 6.8M | 10.6M | |
48.7M | 48.7M | 94.8M | 41.6M | 11.4M | 71.5M | -18.2M | 68.8M | -8.3M | -115.6M | 11M | 14.1M | 57.6M | -20.8M | 25.3M | -11.4M | -8.8M | -7.5M | -6.7M | -5.3M |
SIGA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 05, 2025 | August 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 05, 2025 | June 30, 2025 | 2025 |
Continue your SIGA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.